Islam Baiev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail
BOSTON - A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year. Unfortunately, cancer cells often develop additional mutations that make them resistant to such targeted drugs, resulting in disease relapse. Now researchers led by a team at Massachusetts General Hospital (MGH) have identified the first resistance mechanisms that may occur to these drugs and identified strategies to overcome them. The findings are published in ....

United States , Mustafa Sakhi , Samuel Klempner , Mohammed Syed , Giulia Siravegna , Aaron Hata , Meagan Ryan , Jochen Lennerz , Chendi Li , Junbing Zhang , Alexa Michel , Bryan Corcoran , Leslie Kiedrowski , Jessicaj Lin , Noritaka Tanaka , Dejan Juric , Justin Gainor , Islam Baiev , Cancer Research , Termeer Center , Mark Foundation For Cancer Research , Drug Administration , Gastrointestinal Cancer Center Program , American Cancer Society , Massachusetts General Hospital , Thoracic Cancers ,